Navigation Links
OHK Medical Devices appoints Mr. Omer Inbar as Chief Executive Officer
Date:4/18/2013

Haifa, Israel (PRWEB) April 18, 2013

OHK Medical Devices Ltd., manufacturer of the HemaClear® single-use, sterile exsanguinating tourniquet device, announced today that it has appointed Mr. Omer Inbar as Chief Executive Officer.

Previously, Mr. Inbar served as Vice President of Sales and was instrumental in strong revenue growth of Hemaclear over the past two years.

“We are excited to announce the appointment of Mr. Omer Inbar as CEO. We would also like to thank our outgoing CEO Mr. Oren Gavriely for his last 6 years of dedication and service as CEO,” said Baruch Halpert, Chairman, OHK Medical Devices. Mr. Halpert added that “Mr. Inbar has already proved himself as a strong leader, and has been a key factor to the companies success over the last two years.”

Inbar brings valuable experience from his previous position heading international sales and marketing efforts for the company. “I am thrilled to be leading a young and talented team through this next phase of growth,” Inbar commented. “This is an exciting time for the company as we continue to grow our flagship HemaClear product as the tourniquet of choice by hospitals worldwide, and begin to introduce new generation HemaClear products and additional technologies to the market. I would like to thank Oren for his years of committed service to the company, bringing the company to profitable growth and assembling a superb leadership team that will continue to deliver outstanding products to the medical devices industry," Inbar concluded.

About HemaClear®

HemaClear® is the world’s leading sterile tourniquet with a simple yet innovative technology, representing a new standard of care in bloodless orthopedic surgery. Since entering the market in 2007 this product has been successfully used in almost 500,000 procedures. Easier, cheaper and safer than the standard offerings, HemaClear® represents the first significant advancement in tourniquet technology in over 100 years. HemaClear® was developed by OHK Medical Devices (OHK), a privately held company based in Haifa, Israel and the United States and is currently used in over 2000 operating rooms across 30 countries. For more information about HemaClear®, visit http://www.hemaclear.com.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10646509.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Maryville, Tennessee Based Molecular Pathology Laboratory Network (MPLN) Celebrates 38th Annual Medical Laboratory Professional Week by Honoring Employees
2. Nebraska Medical Center Implants States First SynCardia Total Artificial Heart
3. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
4. BioClinica Releases Integrated Medical Image Management Solution
5. Surefire Medical Launches Next Generation Infusion System ST-LT and Specialty Catheters at SIR - Maximizing Targeted Delivery of Embolics Without Reflux
6. AtheroNova Adds New Medical Advisor
7. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
8. “Scientific And Medical Research On The Successful Treatment Of Type 1 + 2 Diabetes With Alkaline Reduced Water” is Reviewed in Today’s Bawell Water Ionizer Health Report
9. Dermatology Associates Medical Group in Beverly Hills Announces Safe, Fast Anti-Aging Laser Treatment
10. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
11. Medical Marijuana Inc., Corporate Update- Significant Revenue and Net Income Growth 1st Quarter- Division and Corporate Holdings Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
Breaking Biology News(10 mins):